Pricing Log in Create free account
Saturday 17 October 2026 Export NXGL’s income statement to Excel — free account

NexGel, Inc.

NXGL Healthcare Medical Instruments & Supplies

NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024. In the quarter to June 2026, revenue grew 27.8%, EPS fell 344.4%, free cash flow fell 432.3% and total debt rose 353.8%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for five.

5.59 0.41 +7.92%
Market cap
$15.9M
P/E
0.0×
Fwd P/E
−4.7×
Dividend yield
—
F-score
5/9
Altman Z
24.63
Beneish M
−3.41
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 1 — — — — 1 4 — — — —
Insider Ownership 95.34%

Capital & Financial Ratios $m

Market Cap 15.92
Revenue 12.07
Net Income (6.05)
Free Cash Flow (3.34)
Net Debt 1.99
Current Ratio 0.43 (below 1: weak)
Debt/Equity 0.68
P/E ratio 0.00
Fwd P/E (4.67) (negative: loss-making)
P/S ratio 4.18
P/B ratio 9.22 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth (147.37%) (below 0%: weak)
Next Y EPS Growth 76.60% (at or above 15%: strong)
Next Y revenue growth 38.25% (at or above 10%: strong)
Next 5Y EPS Growth 49.14% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.3×, against a ten-year median of 60.2×; over the ten years it ranged from 2.8× in 2026 to 122× in 2022.
P/S against its own 10 years 1.90%
10-year low 10-year high
P/B against its own 10 years 2.73%
10-year low 10-year high
EV/Sales against its own 10 years 1.90%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 3 2 1 2
Receivables 1 1 1 1
Inventory 1 2 2 2
Other — — — —
5 5 4 6
2023 2024 2025 Q'26
Payables 1 1 1 4
ST’ Debt — — — —
Other 1 0 — 9
3 2 3 14

Compound Annual Growth %

10y 5y 3y
Sales — 76.12% 77.33%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 133.15% (13.80%)

Revenue $m

Mar Jun Sep Dec Year
’26 3 4 — — —
’25 3 3 3 3 11
’24 1 1 3 3 9
’23 1 1 1 1 4
’22 0 1 1 1 2
’21 0 0 0 1 2
’20 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (2) — — —
’25 0 0 (1) 0 (1)
’24 (1) (1) (1) (1) (4)
’23 (1) (1) (1) (1) (3)
’22 (1) (1) (1) (1) (3)
’21 0 (1) (1) (1) (3)
’20 (1) 0 0 0 (2)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (2) — — —
’25 0 0 (1) 0 (1)
’24 (1) (1) (1) (1) (4)
’23 (1) (1) (1) (1) (4)
’22 (1) (1) (1) (1) (3)
’21 (1) (1) (1) (1) (3)
’20 (1) 0 0 (1) (2)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.11) (0.40) — — —
’25 (0.09) (0.09) (0.08) (0.12) (0.38)
’24 (0.14) (0.14) (0.11) (0.11) (0.50)
’23 (0.15) (0.12) (0.10) (0.19) (0.56)
’22 (0.33) (0.19) (0.22) (0.11) (0.85)
’21 (0.24) (0.28) (0.38) (0.54) (1.45)
’20 (0.01) (0.01) (0.01) (0.98) (1.00)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 51.00 21.80 23.60 36.80 29.00

Analyst estimates 2026–2028

Powerpack
High — — — — — 93.20 72.40 61.00 102.00 90.50
People
People Employees — — — — — 10 12 19 19 19
Revenue/emp, $m — — 0.00 0.00 0.00 0.16 0.17 0.22 0.46 0.60
Income, $m
Income, $m Revenue — — 2 1 1 2 2 4 9 11
Gross margin, % — — 21.92 (22.45) (43.18) 0.52 12.50 9.15 31.63 39.48
EBT — — (2) (2) (2) (4) (5) (3) (3) (3)
EBT margin, % — — (85.31) (268.20) (335.91) (277.89) (231.74) (77.97) (39.86) (25.33)
Net income — 0 (2) (2) (2) (4) (5) (3) (3) (3)
Depreciation — — 0 0 0 2 1 0 1 1
Per share, $
Per share, $ Revenue — — 0.44 0.05 0.30 0.52 0.37 0.72 1.33 1.45
Earnings — — (0.38) (0.14) (1.00) (1.45) (0.85) (0.56) (0.50) (0.38)
Cash flow — — (0.31) (0.13) (0.80) (0.92) (0.54) (0.57) (0.59) (0.17)
Capex — — 0.00 0.00 (0.14) (0.09) (0.02) (0.12) (0.07) (0.01)
Free cash flow — — (0.31) (0.13) (0.94) (1.01) (0.55) (0.69) (0.66) (0.18)
Book value — — 0.06 0.03 0.03 4.06 1.37 0.91 0.93 0.62
Shares, m — — 5 14 2 3 6 6 7 8
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — 187.25 187.25 187.25 100.29 73.50 62.42 66.86 22.14
P/B — — 433.31 433.31 433.31 12.87 19.71 49.41 95.54 51.71
EV/Sales — — 186.38 186.38 186.38 91.86 70.41 61.89 66.76 22.12
EV/FCF — — (82.54) (82.54) (82.54) (47.15) (48.60) (64.36) (134.58) (174.49)
Cash, $m
Cash, $m Operating cash flow — — (2) (2) (2) (3) (3) (3) (4) (1)
Capex — — — — 0 0 0 (1) 0 0
Free cash flow — — (2) (2) (2) (3) (3) (4) (4) (1)
Balance, $m
Balance, $m Working capital — — 0 0 (1) 11 7 3 3 1
Total debt — — — 1 0 0 0 1 1 1
Net debt — — — 1 0 (13) (6) (2) (1) 0
Shareholders’ equity — — 0 0 0 12 8 5 6 5
Returns, %
Returns, % ROA — — (510.96) (146.29) (109.19) (44.80) (34.72) (31.09) (31.34) (27.98)
ROIC — — 0.00 0.00 (478.81) 0.00 (161.46) (72.95) (42.98) (45.90)
ROE — — (571.26) (581.85) (1,003.99) (70.91) (48.13) (49.32) (58.35) (54.69)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

NexGel, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HBIO Harvard Bioscience, Inc. $37.8M — (loss-making) — (loss-making) +11.13% (above 0%: growing) n/m −123.43% (below 0%: shrinking) 55.57% (4.30%) Compare
MLSS Milestone Scientific, Inc. $29.6M — (loss-making) — (loss-making) +22.27% (above 0%: growing) n/m +66.68% (above 0%: growing) 67.24% (37.37%) Compare
RVP Retractable Technologies, Inc. $17.6M — (loss-making) 11.1× −31.07% (below 0%: shrinking) n/m +56.67% (above 0%: growing) 2.65% (71.46%) Compare
BNGO Bionano Genomics, Inc. $16.1M — (loss-making) — (loss-making) +21.36% (above 0%: growing) n/m −33.93% (below 0%: shrinking) 52.80% (88.34%) Compare
NXGL NexGel, Inc. $15.9M — (loss-making) — (loss-making) +27.81% (above 0%: growing) n/m −432.32% (below 0%: shrinking) 30.09% (67.96%)
FEMY Femasys Inc. $14.5M — (loss-making) — (loss-making) −18.93% (below 0%: shrinking) n/m +11.29% (above 0%: growing) 57.08% (1,526.79%) Compare
CUPR Cuprina Holdings (Cayman) Limited $11.5M — — — — — — — Compare
RGNT Regentis Biomaterials Ltd. $10.9M — — — — −132.79% (below 0%: shrinking) — — Compare
LUCY Innovative Eyewear, Inc. $7.3M — (loss-making) — +74.46% (above 0%: growing) n/m +9.61% (above 0%: growing) 24.00% (168.73%) Compare
Median of peers $15.3M — — +16.25% — +9.61% 54.18% (79.90%)

All 55 Medical Instruments & Supplies stocks →

NexGel, Inc. (NXGL) key facts

  • Concern: NexGel, Inc. reported a net loss of $2.9 million, or a loss of $0.38 per share, for fiscal 2025.
  • Strength: NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024.
  • NexGel, Inc. (NXGL) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, NXGL traded at $5.59, a market capitalization of $15.9 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.2× sales.
  • Return on equity was −54.7% and debt-to-equity 0.68.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 24.63 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

NexGel, Inc. (NXGL) Latest News

10 Mar

Impact 5 ·
stockrow.com/NXGL · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com